A new medicine called ONC201 for acute myeloid leukemia
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10891412
This research explores a new medicine, ONC201, to improve treatment for people with acute myeloid leukemia (AML).
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10891412 on ClinicalTrials.gov |
What this research studies
We are conducting a clinical trial to learn more about ONC201, a new type of medicine that works by targeting a specific survival mechanism within leukemia cells. Our earlier laboratory work showed that ONC201 can cause AML cells to die without harming healthy cells, and it appears especially effective against AML that is resistant to other treatments. We also found that ONC201 may eliminate leukemia stem cells, which are often responsible for the disease coming back. Early results from other trials suggest ONC201 is well-tolerated and shows promising signs of activity.
Who could benefit from this research
Good fit: Ideal candidates for this opportunity would be patients diagnosed with acute myeloid leukemia (AML).
Not a fit: Patients without acute myeloid leukemia would not receive direct benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this medicine could lead to higher cure rates for acute myeloid leukemia, particularly for patients whose disease is resistant to current therapies.
How similar studies have performed: Early trials of ONC201 have shown good tolerability and initial signs of clinical response.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDREEFF, MICHAEL — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: ANDREEFF, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.